Caplin Point Laboratories Surges to 52-Week High

Caplin Point Laboratories, a midcap pharmaceutical company, has recently seen a surge in its stock price, reaching a 52-week high on December 22, 2023. The stock has been performing well in the market, outperforming the sector by 5.24% today. According to MarketsMOJO, a leading financial analysis platform, the stock is currently rated as 'Hold'. The stock has been on a consecutive gain for the past two days, with a 8.12% increase in returns during this period. Today, the stock touched an intraday high of Rs 1389.95, showing a 6.71% increase. Caplin Point Laboratories is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in the market. In the past year, the company has shown a remarkable performance with a 95.27% increase in its stock price, while the Sensex has only seen a 16.47% increase. As a midcap company in the pharmaceutical industry, Caplin Point Laboratories has been making strides in the market with its consistent growth and positive performance. With its recent surge in stock price, the company is definitely one to watch out for in the coming days.